Home >> CAP TODAY Recommends >> Precision medicine conference for health network/hospital CEOs to take place Sept. 12–13

Precision medicine conference for health network/hospital CEOs to take place Sept. 12–13

Print Friendly, PDF & Email

Precision medicine strategies and successes in improving patient outcomes are key themes when hospital and health network CEOs and administrators gather in Nashville Sept. 12–13 to hear from innovators at Vanderbilt University Medical Center, Geisinger Health, Northwell Health, Moffitt Cancer Center, and Seattle Children’s Hospital, among others.

“Precision Medicine for Hospital CEOs: What You Need to Know about Genetic Testing, Precision Medicine, and Population Health Management” (https://www.precisionmedicineforhospitals.com) will feature first-mover and early-adopter health networks sharing the strategies of their precision medicine programs and the patient care successes and outcomes.

Keynote speaker is Jeffery Balser, MD, PhD, CEO of Vanderbilt University Medical Center, which is internationally recognized for its pioneering efforts to bring precision medicine into daily clinical care. Attendees will gain insight into the early successes of precision medicine at Vanderbilt and learn how the health care big data base at Vanderbilt is being used to inform population health initiatives while also guiding the care clinicians provide daily.

Among the 20 speakers sharing their experiences at bringing precision medicine, genetic medicine, and genetic testing into the daily care provided to their patients will be:

  • Mark Van Oene, senior vice president and chief commercial officer, Illumina: Envisioning the Future of Genomics in Clinical Care and Genetic Testing and Gene Sequencing’s Role in Precision Medicine.
  • Huntington F. Willard, PhD, director, Geisinger National Precision Health: A Clinical Imperative: Genomics, Population Health, and Precision Medicine at Geisinger Health.
  • Howard L. McLeod, PharmD, medical director, Personalized Medicine Institute, Moffitt Cancer Center: Precision Medicine in Oncology/Cancer Care.
  • Julie A Johnson, PharmD, dean, College of Pharmacy, University of Florida: Precision Medicine in Pharmacogenomics.
  • Josh Denny, MD, vice president of personalized medicine, Vanderbilt University Medical Center: Genetic and Molecular Data in Population Health.

Two sessions of particular interest involve how health care organizations are using precision medicine with providers in arrangements that are delivering substantial reimbursement in shared savings arrangements with major health plans. They are:

  • Philip Chen, MD, PhD, chief healthcare informatics officer, Sonic Healthcare USA: Case Study of Precision Medicine Shared Saving Initiative: Use of Healthcare Big Data, Lab Results, and Analytics to Support Office-Based Physicians in Managing Patients with Diabetes and Chronic Diseases.
  • Richard VanNess, MS, product manager, TriCore Reference Laboratories: Partnering with Payers: How Our Health Network Helps to Achieve Better Patient Outcome at Less Cost in Shared Savings Arrangements.
    For more information and to register, go to https://www.precisionmedicineforhospitals.com (or copy and paste this URL in your browser: https://www.precisionmedicineforhospitals.com). Or contact Chris Garcia at 512-264-7103.
x

Check Also

Molecular ‘bucket list’ for renal cancer

September 2018—Leo Tolstoy is not listed as a coauthor on the most recent iteration of The Cancer Genome Atlas on renal cell carcinoma, which focuses on molecular characterization of RCC. But the topic is as rich and complex as a Russian novel, and the authors’ approach is so comprehensive, it’s tempting to picture them at least holding forth at a certain soirée in Saint Petersburg (minus the after-party drunkenness and the bit with a bear, of course). The project may not be as sprawling as War and Peace, which marches 559 characters, speaking two languages, over four volumes, 15 parts, and 333 chapters. It’s a heroic effort nonetheless. There is much to keep track of in renal cell carcinoma, both generally and in this latest document, which evaluates 843 RCCs from three major histologic subtypes, including 488 clear cell RCC, 274 papillary RCC, and 81 chromophobe RCC.

X